# Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

> **NCT06054815** · PHASE2 · COMPLETED · sponsor: **NeuroBo Pharmaceuticals Inc.** · enrollment: 109 (actual)

## Conditions studied

- NON-ALCOHOLIC STEATOHEPATITIS

## Interventions

- **DRUG:** DA-1241
- **DRUG:** Sitagliptin
- **DRUG:** DA-1241 Placebo
- **DRUG:** Sitagliptin Placebo

## Key facts

- **NCT ID:** NCT06054815
- **Lead sponsor:** NeuroBo Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-14
- **Primary completion:** 2024-10-24
- **Final completion:** 2024-10-30
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06054815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06054815, "Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06054815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*